Molecular Classification of Medulloblastoma

Area of Science:

• Pediatric Oncology
• Neuro-oncology
• Genomics

Background:

• Medulloblastoma (MB) is a frequent pediatric malignant brain tumor.
• Current treatments (surgery, radiation, chemotherapy) improve survival but cause significant morbidity.
• Existing risk stratification relies on clinical factors like age, metastasis, and residual tumor.

Purpose of the Study:

• To highlight the heterogeneity of medulloblastoma based on molecular subgroups.
• To emphasize the need for molecular classification in refining risk stratification.
• To explore the potential for identifying novel therapeutic strategies through molecular subtyping.

Main Methods:

• Review of current standard treatment regimens for MB.
• Analysis of clinical factors used in MB risk stratification.
• Integration of recent genomic studies identifying distinct molecular subgroups (WNT, SHH, Group 3, Group 4).

Main Results:

• MB comprises at least four distinct molecular subgroups: WNT, SHH, Group 3, and Group 4.
• WNT MB shows the best prognosis; SHH MB has an intermediate prognosis.
• Group 3 MB has a poor prognosis due to frequent metastasis; Group 4 MB (most common) has an intermediate prognosis and can be metastatic.

Conclusions:

• Medulloblastoma is a heterogeneous disease with distinct molecular, demographic, and clinical characteristics across subgroups.
• Molecular classification is redefining MB risk stratification.
• Understanding molecular subgroups offers potential for developing targeted therapeutic strategies.